Greg Meadows, CEO at United Skin Specialists has over two decades of experience in progressive leadership roles within multiple healthcare service companies. As CEO of United Skin Specialists, Greg oversees the entire USS partner network of Midwestern dermatology practices and profitable growth through acquisitions and de novos. Greg works closely with the Medical Advisory Board of USS to ensure physician leadership and decision-making throughout the organization.
Most recently, Greg was Chief Executive Officer at Rocky Mountain Healthcare, a group of family medicine, urgent care and physical therapy clinics throughout the Denver Colorado metro area. Greg recruited and retained a professional management team which stabilized the company and drove profitable growth at greater than market rates, significantly enhanced the quality of the provider pool, drove patient satisfaction scores, opened de novo clinics, achieved sustained profitability and led the organization through a transaction in early 2018.
From March 2014 to October 2016, he served as President and Chief Operating officer at Home Infusion Solutions, LLC, the independent leader in home infusion services on the east coast of the United States. He was responsible for leading sales, operations, customer service, and managed care for the rapidly-growing home infusion company. During his tenure, the company began a profitable growth trajectory that exceeded 20% YoY for its core therapies and new patient admits, which drove significant profit increases as well as patient and referral source satisfaction. This work culminated in a transaction with a publicly traded company.
Prior to Home Infusion Solutions, Greg was President and Chief Executive Officer for Multispecialty Physician Partners, LLC, a provider of revenue cycle management, staffing, administration, marketing, I.T. and other practice management services to physicians’ practices in Colorado and Texas.
From August 2008 to May 2013, Greg served as President, CoramRX and Executive Vice President, Managed Markets and Pricing. While serving on their executive leadership team, Coram became one of the top-performing healthcare companies in the U.S., with a double-digit compounded annual growth rate and an EBITDA increase of more than 250%. This work culminated in a subsequent transaction with a publicly traded company. Greg served in multiple roles with Schering-Plough Pharmaceuticals from January 1996 to August 2008. These roles included sales leadership for all specialty products, government affairs and pricing and contracting leadership for all specialty products.
Greg received his undergraduate degree from Louisiana State University and his Masters of Public Administration from Louisiana State University.